Publications New

May 30, 2023 Cell Rep

Human papillomavirus e5 suppresses immunity via inhibition of the immunoproteasome and sting pathway

Miyauchi S, Kim SS, Jones RN, Zhang L, Guram K, Sharma S, Schoenberger SP, Cohen EEW, Califano JA, Sharabi AB

May 29, 2023 Cell Rep Med

Targets and cross-reactivity of human T cell recognition of common cold coronaviruses

Tarke A, Zhang Y, Methot N, Narowski TM, Phillips E, Mallal S, Frazier A, Filaci G, Weiskopf D, Dan JM, Premkumar L, Scheuermann RH, Sette A, Grifoni A

May 12, 2023 Sci Immunol

Transcriptional programming of CD4+ TRM differentiation in viral infection balances effector- and memory-associated gene expression

Nguyen QP, Takehara KK, Deng TZ, O'Shea S, Heeg M, Omilusik KD, Milner JJ, Quon S, Pipkin ME, Choi J, Crotty S, Goldrath AW

May 12, 2023 Nat Commun

Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response.

Pagadala M, Sears TJ, Wu VH, Pérez-Guijarro E, Kim H, Castro A, Talwar JV, Gonzalez-Colin C, Cao S, Schmiedel BJ, Goudarzi S, Kirani D, Au J, Zhang T, Landi T, Salem RM, Morris GP, Harismendy O, Patel SP, Alexandrov LB, Mesirov JP, Zanetti M, Day CP, Fan CC, Thompson WK, Merlino G, Gutkind JS, Vijayanand P, Carter H.

May 9, 2023 Immunity

DNA architectural protein CTCF facilitates subset-specific chromatin interactions to limit the formation of memory CD8+ T cells

Quon S, Yu B, Russ BE, Tsyganov K, Nguyen H, Toma C, Heeg M, Hocker JD, Milner JJ, Crotty S, Pipkin ME, Turner SJ, Goldrath AW

May 7, 2023 bioRxiv

Linked CD4 + /CD8 + T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression

Dolina JS, Lee J, Brightman SE, McArdle S, Hall SM, Thota RR, Lanka M, Premlal ALR, Greenbaum JA, Cohen EEW, Peters B, Schoenberger SP

May 6, 2023 Int Immunol

An update on studies characterizing adaptive immune responses in SARS-CoV-2 infection and COVID-19 vaccination

da Silva Antunes R, Grifoni A, Frazier A, Weiskopf D, Sette A

May 5, 2023 bioRxiv

Linked CD4 + /CD8 + T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression

Joseph S Dolina, Joey Lee, Spencer E Brightman, Sara McArdle, Samantha M Hall, Rukman R Thota, Manasa Lanka, Ashmitaa Logandha Ramamoorthy Premlal, Jason A Greenbaum, Ezra E W Cohen, Bjoern Peters, Stephen P Schoenberger

May 5, 2023 Front Immunol

Evidence for broad cross-reactivity of the SARS-CoV-2 NSP12-directed CD4+ T-cell response with pre-primed responses directed against common cold coronaviruses

Westphal T, Mader M, Karsten H, Cords L, Knapp M, Schulte S, Hermanussen L, Peine S, Ditt V, Grifoni A, Addo MM, Huber S, Sette A, Lütgehetmann M, Pischke S, Kwok WW, Sidney J, Schulze Zur Wiesch J

May 1, 2023 NPJ Vaccines

Publications New

Human papillomavirus e5 suppresses immunity via inhibition of the immunoproteasome and sting pathway

Targets and cross-reactivity of human T cell recognition of common cold coronaviruses

Transcriptional programming of CD4+ TRM differentiation in viral infection balances effector- and memory-associated gene expression

Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response.

DNA architectural protein CTCF facilitates subset-specific chromatin interactions to limit the formation of memory CD8+ T cells

Linked CD4 + /CD8 + T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression

An update on studies characterizing adaptive immune responses in SARS-CoV-2 infection and COVID-19 vaccination

Linked CD4 + /CD8 + T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression

Evidence for broad cross-reactivity of the SARS-CoV-2 NSP12-directed CD4+ T-cell response with pre-primed responses directed against common cold coronaviruses

A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG

T cell responses to SARS-CoV-2

Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox